Based on the Nuvation Bio Inc stock forecast from 4 analysts, the average analyst target price for Nuvation Bio Inc is USD 6.43 over the next 12 months. Nuvation Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Nuvation Bio Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Nuvation Bio Inc’s stock price was USD 2.89. Nuvation Bio Inc’s stock price has changed by +12.02% over the past week, +30.77% over the past month and +127.56% over the last year.
No recent analyst target price found for Nuvation Bio Inc
No recent average analyst rating found for Nuvation Bio Inc
Company Overview Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. Read Less
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control...Read More
Frequently Asked Questions About Nuvation Bio Inc (NUVB) Stock
Based on ratings from 4 analysts Nuvation Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on NUVB's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for NUVB is USD 6.43 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on NUVB's stock to indicate if its overvalued.
The last closing price of NUVB's stock was USD 2.89.
The most recent market capitalization for NUVB is USD 0.87B.
Based on targets from 4 analysts, the average taret price for NUVB is projected at USD 6.43 over the next 12 months.
This means that NUVB's stock price may go up by +122.44% over the next 12 months.
We can't find any ETFs which contains Nuvation Bio Inc's stock.
As per our most recent records Nuvation Bio Inc has 203 Employees.
Nuvation Bio Inc's registered address is 1500 Broadway, New York, NY, United States, 10036.
You can get more information about it from Nuvation Bio Inc's website at https://www.nuvationbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Nuvation Bio Inc (NUVB) Stock
Based on ratings from 4 analysts Nuvation Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on NUVB's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for NUVB is USD 6.43 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on NUVB's stock to indicate if its overvalued.
The last closing price of NUVB's stock was USD 2.89.
The most recent market capitalization for NUVB is USD 0.87B.
Based on targets from 4 analysts, the average taret price for NUVB is projected at USD 6.43 over the next 12 months.
This means that NUVB's stock price may go up by +122.44% over the next 12 months.
We can't find any ETFs which contains Nuvation Bio Inc's stock.
As per our most recent records Nuvation Bio Inc has 203 Employees.
Nuvation Bio Inc's registered address is 1500 Broadway, New York, NY, United States, 10036.
You can get more information about it from Nuvation Bio Inc's website at https://www.nuvationbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NUVB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
